Alto Neuroscience investors, securities fraud class action lawsuit deadline approaching.

Bernstein Liebhard LLP reminds Alto Neuroscience investors of an upcoming deadline in a securities fraud class action lawsuit. Investors who purchased shares between February 2, 2024, and October 22, 2024, may be eligible to join the lawsuit. Those who lost money in their investment are encouraged to visit Alto Neuroscience Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com.

Alto Neuroscience, Inc. (NYSE: ANRO) investors who purchased shares between February 2, 2024, and October 22, 2024, are urged to take action and join a securities fraud class action lawsuit. Bernstein Liebhard LLP has reminded investors of an upcoming deadline, highlighting the opportunity to seek compensation for losses incurred.

The lawsuit alleges that Alto Neuroscience made false and misleading statements regarding the effectiveness of its product, ALTO-100, in treating major depressive disorder (MDD). The company overstated the clinical, regulatory, and commercial prospects of ALTO-100, leading investors to believe in inflated business and financial prospects. When the true details emerged, investors suffered damages.

Investors who purchased shares during the specified period and suffered losses are encouraged to visit the Alto Neuroscience Shareholder Class Action Lawsuit page or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to learn more about the lawsuit and their rights.

The deadline for investors to join the lawsuit is September 19, 2025. Bernstein Liebhard LLP is a prominent law firm specializing in securities class action lawsuits and shareholder rights litigation, with a history of securing significant settlements for investors.

Investors are advised to act promptly to ensure they do not miss the opportunity to seek compensation for their losses.

References:
[1] https://www.morningstar.com/news/pr-newswire/20250901dc62345/anro-deadline-anro-investors-with-losses-in-excess-of-100k-have-opportunity-to-lead-alto-neuroscience-inc-securities-fraud-lawsuit